- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 25.09. | Raymond James startet Coverage für Seaport Therapeutics mit "Strong Buy" - Potenzial bei Depressionsmedikament | 2 | Investing.com Deutsch | ||
| 25.09. | Raymond James initiates Seaport Therapeutics stock coverage with strong buy on depression drug potential | 1 | Investing.com | ||
| 23.09. | Seaport Therapeutics: Wirkstoff-Pipeline gewinnt an Dynamik | - | Investing.com Deutsch | ||
| 09.09. | Seaport Therapeutics stellt auf Citigroup-Konferenz Pläne für Glyph-Plattform und Pipeline vor | 1 | Investing.com Deutsch | ||
| 09.09. | Seaport Therapeutics meldet positive Ergebnisse aus Phase-1-Studie | 1 | Investing.com Deutsch | ||
| 09.09. | Seaport Therapeutics reports positive phase 1 trial results | 1 | Investing.com | ||
| SEAPORT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 09.09. | PureTech Health PLC - PRTC's SPTX: New Positive Phase 1 GlyphAllo Data | 9 | RNS | ||
| 25.08. | Jones Trading startet Coverage für Seaport Therapeutics mit Kaufempfehlung | 1 | Investing.com Deutsch | ||
| 25.08. | Jones Trading initiates Seaport Therapeutics stock with buy rating | 3 | Investing.com | ||
| 20.08. | H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy | 1 | Investing.com | ||
| 04.08. | H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy | 1 | Investing.com | ||
| 03.08. | Seaport Therapeutics, Inc. GAAP EPS of -$1.78 | 1 | Seeking Alpha | ||
| 03.08. | Seaport Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 03.08. | Seaport Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.07. | Seaport Therapeutics stock initiated at buy by H.C. Wainwright | 1 | Investing.com | ||
| 09.06. | Stifel reiterates Buy on Seaport Therapeutics stock, $30 target | 1 | Investing.com | ||
| 09.06. | Seaport Therapeutics reports positive phase 1 data for GlyphAgo | 1 | Investing.com | ||
| 09.06. | Seaport Therapeutics meldet positive Phase-1-Daten für GlyphAgo | 2 | Investing.com Deutsch | ||
| 09.06. | PureTech Health PLC - PRTC's SPTX: New Positive GlyphAgo Ph1 Dosing Data | 1 | RNS | ||
| 08.06. | Seaport Therapeutics, Inc. GAAP EPS of -$10.34 | 1 | Seeking Alpha |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| GILEAD SCIENCES | 127,82 | -0,58 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences | Two-year extension builds on productive relationship established in 2019 Nurix continues to retain co-development and 50/50 profit sharing options on up to two programs in the United States BRISBANE... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 451,75 | +0,78 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| IONIS PHARMACEUTICALS | 38,360 | -0,85 % | Genentech, Ionis Reveal Positive Interim Data From Phase III Sefaxersen Study In IgA Nephropathy | SOUTH SAN FRANCISCO (dpa-AFX) - Genentech, affiliated to Swiss drug major Roche Holding AG (RHHBY, RO.SW, ROG.SW), and partner Ionis Pharmaceuticals, Inc. (IONS) announced Wednesday positive... ► Artikel lesen | |
| UNITED THERAPEUTICS | 481,30 | +0,06 % | United Therapeutics Wins Patent Case Against Liquidia | WASHINGTON (dpa-AFX) - Wednesday, United Therapeutics Corporation (UTHR) announced that the U.S. District Court for the District of Delaware ruled that Liquidia Technologies (LQDA) infringed... ► Artikel lesen | |
| BRIDGEBIO PHARMA | 60,36 | +1,00 % | BridgeBio Pharma, Inc.: BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels | - In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated HS troponin I at baseline, 100% treated with BBP-418 returned to the normal range by Month 12 versus... ► Artikel lesen | |
| BAYER | 44,600 | -1,01 % | Bayer-Aktie: Reicht die Kraft für den nächsten Ausbruch? | Bayer zählt zu den größten Pharma- und Agrarchemiekonzernen der Welt und hat in dieser Woche die psychologische 50-Euro-Marke überschritten. Der Kurs nähert sich seinem Julihoch, während Analysten optimistischer... ► Artikel lesen | |
| MERCK KGAA | 136,65 | +1,82 % | Merck Aktie | Wichtige Durchschnittslinien durchbrochen | Analyse | ||
| NOVO NORDISK | 32,920 | -0,48 % | Novo-Nordisk-Aktie: 12,4% gegen 9,1% - die Wende? | Die Novo-Nordisk-Aktie notiert mit rund 253 DKK weiterhin weit unter ihren früheren Höchstständen. Ausgerechnet der bereits abgeschriebene Hoffnungsträger CagriSema liefert nun ein neues Lebenszeichen:... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 55,42 | 0,00 % | Eton Pharmaceuticals, Inc. - 8-K, Current Report | ||
| GENERATE BIOMEDICINES | 13,685 | 0,00 % | Generate Biomedicines, Inc.: Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of 'Armored' CAR T Therapy for Ovarian Cancer | Engineered with AI to optimize T-cell function in solid tumors, GB-5267 is the first next-generation cell therapy for ovarian cancer to enter clinical trials First patient treated in new clinical... ► Artikel lesen | |
| LB PHARMACEUTICALS | 37,080 | 0,00 % | Needham initiates LB Pharmaceuticals stock with buy rating | ||
| BIOHAVEN | 12,870 | 0,00 % | Biohaven Ltd.: Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 | Oral presentation selected: Phase 1 findings from the ongoing BHV1530-101 study will be featured in an oral presentation at the 38th EORTC-NCI-AACR Symposium on... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,555 | 0,00 % | Aquestive appoints Rich Daly to board of directors | ||
| OMNIAB | 4,860 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| APNIMED | 21,530 | 0,00 % | Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
SEAPORT THERAPEUTICS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 18,420 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SEAPORT THERAPEUTICS INC finden Sie auf Wallstreet Online.